Pulmonary arterial hypertension (PAH) is a rare and progressive condition caused by high blood pressure in the arteries that ...

Using nationwide networks, advanced cytokine profiling, and patient clustering, the team screened over 100 PAH patients to ...

Pharmaceuticals’ treatment of pulmonary arterial hypertension was granted FDA orphan designation status, according to a post to ...

Angiotensin-converting enzyme (ACE) inhibitor therapy may reduce all-cause mortality in idiopathic pulmonary fibrosis (IPF) but not in COPD.

Apple Watch users can now get alerts for potential high blood pressure. watchOS 26 adds hypertension notifications on select models for early monitoring. Apple has expanded its hypertension ...

Having high blood pressure is one of the most common lifestyle diseases most people suffer from due to their fast-paced and stressful lives. However, "high blood pressure doesn’t always need fancy ...

High blood pressure, a silent killer, affects 15 per cent of Singapore residents and can be managed with exercise, diet and stress reduction. Experts recommend aerobic exercise, caution against ...

Tvardi Therapeutics has failed its first big test as a public company. Months after joining the Nasdaq, the biotech has reported the unappetizing mix of high dropout rates and placebolike efficacy in ...

Long-term data shows significant and sustained blood pressure reductions in both office-based and 24-hour ambulatory blood pressure, reinforcing the durability, safety and effectiveness of the ...

The FDA approved nerandomilast (Jascayd) tablets for idiopathic pulmonary fibrosis (IPF), the first new product for the progressive lung condition in over a decade, the agency announced on Tuesday.